Corbus earlier announced the presentation of data from its US and UK conducted first-in-human dose escalation clinical study of CRB-701 (SYS6002) at the 2025 American Society of Clinical Oncology ...
Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback